Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy

Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy

Low immunogenicity and immunosuppressive tumor microenvironment (TME) are two pivotal factors restricting tumor immunotherapy. Photodynamic therapy (PDT) directly destroys cancer cells by producing reactive oxygen species (ROS), and enhances the immunogenicity of ''cold'' tumors...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Xu, Kehan Liu, Shuqi Mi, Yao Yao, Mengyao Zhang, Shujuan Xue, Feng Zhi, Sally-Ann Cryan, Dawei Ding
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Materials Today Bio
Subjects:
Albumin nanoparticles
Photodynamic therapy
Immunogenic cell death
COX-2/PGE2 inhibition
Immunosuppressive tumor microenvironment
PD-L1 blockade
Online Access:http://www.sciencedirect.com/science/article/pii/S2590006425000882
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Low immunogenicity and immunosuppressive tumor microenvironment (TME) are two pivotal factors restricting tumor immunotherapy. Photodynamic therapy (PDT) directly destroys cancer cells by producing reactive oxygen species (ROS), and enhances the immunogenicity of ''cold'' tumors by inducing immunogenic cell death (ICD), thereby promoting T cell development against tumors. However, PDT also deteriorates immunosuppression through overactivating the cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway. To this end, biocompatible albumin nanoassemblies co-delivering IR780 and diclofenac are herein developed for enhanced therapy against triple-negative breast cancer. PDT-exacerbated PGE2 overexpression is effectively abolished by diclofenac-mediated COX-2 inhibition, which reprograms immunosuppressive TME via downregulating the infiltration of various immunosuppressive cells and their cytokine secretion to enhance effector T cell infiltration. Consequently, the enhanced antitumor immunity effectively inhibits tumor growth, prevents the recurrency and metastasis, and remarkably boosts the treatment efficacy of PD-L1 blockade. This study sets an intriguing example for overcoming the COX-2/PGE2 pathway-exacerbated immunosuppression alongside immune activation, thus enhancing synergistic cancer immunotherapy potentiated by various ROS-producing therapies (e.g., PDT and radiotherapy) and chemotherapy.
ISSN:2590-0064

Similar Items